Trethera Awarded $3 Million NIH Grant to Advance First-In-Class Drug, TRE-515, for the Treatment of Lupus
FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers
FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic Castration Resistant Prostate Cancer
Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045
Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board
Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025
Trethera Treats a Late-Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE-515
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms in Mice
Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress
